• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Vir Biotechnology Inc. (Amendment)

    2/13/24 5:00:42 PM ET
    $VIR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $VIR alert in real time by email
    SC 13G/A 1 formsc13ga.htm

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    Schedule 13G

    (Rule 13d-102)

     

    Information to be Included in Statements Filed Pursuant

    to § 240.13d-1(b), (c) and (d) and Amendments Thereto Filed

    Pursuant to § 240.13d-2

     

    UNDER THE SECURITIES EXCHANGE ACT OF 1934

     

    (Amendment No. 2)*

     

    Vir Biotechnology, Inc.

    (Name of Issuer)

     

    Common Stock

    (Title of Class of Securities)

     

    92764N102

    (CUSIP Number)

     

    December 31, 2023

    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    ☐ Rule 13d-1(b)

    ☐ Rule 13d-1(c)

    ☒ Rule 13d-1(d)

     

    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

     

    CUSIP No. 92764N102 Schedule 13G Page 1 of 7

     

    1

    Names of Reporting Persons

     

    SVF Endurance (Cayman) Limited

    2 Check the Appropriate Box if a Member of a Group (a) ☐
        (b) ☐
    3

    SEC Use Only

     

    4

    Citizenship or Place of Organization

     

    Cayman Islands

    Number of Shares Beneficially Owned by Each Reporting Person With 5

    Sole Voting Power

     

    0

    6

    Shared Voting Power

     

    16,684,041

    7

    Sole Dispositive Power

     

    0

    8

    Shared Dispositive Power

     

    16,684,041

    9

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    16,684,041

    10 Check if the Aggregate Amount in Row (9) Excludes Certain Shares

    Not Applicable
    11 Percent of Class Represented by Amount in Row 9

    12.4%
    12 Type of Reporting Person

    CO

     

     

     

     

    CUSIP No. 92764N102 Schedule 13G Page 2 of 7

     

    1

    Names of Reporting Persons

     

    SoftBank Vision Fund (AIV M1) L.P.

    2 Check the Appropriate Box if a Member of a Group (a) ☐
        (b) ☐
    3

    SEC Use Only

     

    4

    Citizenship or Place of Organization

     

    Delaware

    Number of Shares

    Beneficially Owned by Each Reporting Person With

    5

    Sole Voting Power

     

    0

    6

    Shared Voting Power

     

    16,684,041

    7

    Sole Dispositive Power

     

    0

    8

    Shared Dispositive Power

     

    16,684,041

    9

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    16,684,041

    10

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares

     

    Not Applicable

    11

    Percent of Class Represented by Amount in Row 9

     

    12.4%

    12

    Type of Reporting Person

     

    PN

     

     

     

     

    CUSIP No. 92764N102 Schedule 13G Page 3 of 7

     

    1

    Names of Reporting Persons

     

    SB Investment Advisers (UK) Limited

    2 Check the Appropriate Box if a Member of a Group (a) ☐
        (b) ☐
    3

    SEC Use Only

     

    4

    Citizenship or Place of Organization

     

    England and Wales

    Number of Shares Beneficially Owned by Each Reporting Person With 5

    Sole Voting Power

     

    0

    6

    Shared Voting Power

     

    16,684,041

    7

    Sole Dispositive Power

     

    0

    8

    Shared Dispositive Power

     

    16,684,041

    9

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    16,684,041

    10

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares

     

    Not Applicable

    11

    Percent of Class Represented by Amount in Row 9

     

    12.4%

    12

    Type of Reporting Person

     

    CO

     

     

     

     

    CUSIP No. 92764N102 Schedule 13G Page 4 of 7

     

    ITEM 1. (a) Name of Issuer:

     

    Vir Biotechnology, Inc. (the “Issuer”).

     

      (b) Address of Issuer’s Principal Executive Offices:

     

    1800 Owens Street, Suite 900, San Francisco, CA 94158

     

    ITEM 2. (a) Name of Person Filing:

     

    Each of the following is hereinafter individually referred to as a “Reporting Person” and collectively as the “Reporting Persons.” This statement is filed on behalf of:

     

    SVF Endurance (Cayman) Limited

    SoftBank Vision Fund (AIV M1) L.P. (“SVF”)

    SB Investment Advisers (UK) Limited (“SBIA UK”)

     

      (b) Address or Principal Business Office:

     

    The principal business address of SVF Endurance (Cayman) Limited is c/o Walkers Corporate Ltd., 190 Elgin Avenue, George Town, Grand Cayman KY1-9008, Cayman Islands. The principal business address of SVF is 251 Little Falls Drive Wilmington, DE 19808. The principal business address of SBIA UK is 69 Grosvenor Street, London, W1K 3JP, United Kingdom.

     

      (c) Citizenship of each Reporting Person is:

     

    SVF Endurance (Cayman) Limited is organized under the laws of the Cayman Islands. SVF is organized under the laws of the State of Delaware. SBIA UK is organized under the laws of England and Wales.

     

      (d) Title of Class of Securities:

     

    Common stock, par value $0.0001 per share (“Common Stock”).

     

      (e) CUSIP Number:

     

    92764N102

     

    ITEM 3.

     

    Not applicable.

     

     

     

     

    CUSIP No. 92764N102 Schedule 13G Page 5 of 7

     

    ITEM 4. Ownership.

     

    (a-c)

     

    The ownership information presented below represents beneficial ownership of Common Stock of the Issuer as of December 31, 2023, based upon 134,521,285 shares of Common Stock outstanding as of October 27, 2023, as disclosed in the Issuer’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 3, 2023.

     

    Reporting Person 

    Amount

    beneficially

    owned

      

    Percent

    of class:

       Sole power to vote or to direct the vote:   Shared power to vote or to direct the vote:  

    Sole power to dispose or to direct the disposition

    of:

      

    Shared

    power to

    dispose or

    to direct

    the

    disposition

    of:

     
    SVF Endurance (Cayman) Limited   16,684,041    12.4%   0    16,684,041    0    16,684,041 
    SoftBank Vision Fund (AIV M1) L.P.   16,684,041    12.4%   0    16,684,041    0    16,684,041 
    SB Investment Advisers (UK) Limited   16,684,041    12.4%   0    16,684,041    0    16,684,041 

     

    SVF Endurance (Cayman) Limited is the record holder of the shares of Common Stock reported herein. SVF is the sole owner of SVF Endurance (Cayman) Limited.

     

    SBIA UK has been appointed as alternative investment fund manager (“AIFM”) of SVF. SBIA UK is authorized and regulated by the UK Financial Conduct Authority and is exclusively responsible for making all decisions related to the acquisition, structuring, financing and disposal of SVF’s investments. As a result of these relationships, each of the Reporting Persons may be deemed to share beneficial ownership of the securities reported herein.

     

    ITEM 5. Ownership of Five Percent or Less of a Class.

     

    Not applicable.

     

    ITEM 6. Ownership of More than Five Percent on Behalf of Another Person.

     

    Not applicable.

     

    ITEM 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company.

     

    Not applicable.

     

    ITEM 8. Identification and Classification of Members of the Group.

     

    Not applicable.

     

    ITEM 9. Notice of Dissolution of Group.

     

    Not applicable.

     

    ITEM 10. Certification.

     

    Not applicable.

     

     

     

     

    CUSIP No. 92764N102 Schedule 13G Page 6 of 7

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Date: February 13, 2024

     

      SVF Endurance (Cayman) Limited
       
      By: /s/ Karen Ellerbe
      Name: Karen Ellerbe
      Title: Director
       
      SoftBank Vision Fund (AIV M1) L.P.
       
      By: SB Investment Advisers (UK) Limited, its manager
       
      By: /s/ Amanda Sanchez-Barry
      Name: Amanda Sanchez-Barry
      Title: General Counsel
       
      SB Investment Advisers (UK) Limited
       
      By: /s/ Amanda Sanchez-Barry
      Name: Amanda Sanchez-Barry
      Title: General Counsel

     

     

     

     

    CUSIP No. 92764N102 Schedule 13G Page 7 of 7

     

    LIST OF EXHIBITS

     

    Exhibit No.   Description
    99   Joint Filing Agreement (previously filed).

     

     

     

    Get the next $VIR alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $VIR

    DatePrice TargetRatingAnalyst
    1/29/2024$23.00 → $9.00Overweight → Neutral
    JP Morgan
    9/8/2023$23.00 → $14.00Buy → Neutral
    BofA Securities
    3/6/2023$35.00 → $34.00Neutral → Overweight
    JP Morgan
    2/21/2023$41.00 → $53.00Neutral → Buy
    Goldman
    1/27/2023$18.00 → $30.00Underweight → Equal-Weight
    Morgan Stanley
    9/14/2022$40.00Outperform
    SVB Leerink
    9/9/2022$15.00Underweight
    Morgan Stanley
    3/3/2022$36.00 → $28.00Underperform → Neutral
    Baird
    More analyst ratings

    $VIR
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Vir Biotechnology Provides Corporate Update and Reports First Quarter 2025 Financial Results

      - Initiated Phase 3 registrational ECLIPSE program in chronic hepatitis delta with first patient enrolled in Q1 2025; Program received U.S. FDA Breakthrough and Fast Track designations and EMA PRIME and Orphan Drug designations - Dose escalation continues for PRO-XTEN™ dual-masked T-cell engagers VIR-5818 (HER2) and VIR-5500 (PSMA) - On track to initiate a Phase 1 study of VIR-5525, the PRO-XTEN™ dual-masked EGFR-targeting T-cell engager, in the second quarter of 2025 - 24-week post-treatment data from Phase 2 MARCH study in chronic hepatitis B to be presented at EASL on May 9; Further development requires partner - Strong financial position with approximately $1.0 billion in cash and i

      5/7/25 4:05:00 PM ET
      $VIR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Vir Biotechnology to Provide Corporate Update and Report First Quarter 2025 Financial Results on May 7, 2025

      Vir Biotechnology, Inc. (NASDAQ:VIR) today announced that the Company will provide a corporate update and report financial results for the first quarter ended March 31, 2025, on May 7, 2025. The Company will host a conference call at 1:30 p.m. PT / 4:30 p.m. ET on May 7, 2025. The corporate update and financial results will be provided via a press release shortly after market close and will be accessible on the News page in the Investors section of the Vir Biotechnology website. Participants may access the conference call via webcast on the Events & Presentations page of the Vir Biotechnology website or via phone by dialing the U.S. toll free number +1 (888) 800-8770 or international numbe

      4/30/25 4:05:00 PM ET
      $VIR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Vir Biotechnology to Present Latest Clinical Data in Hepatitis Delta and B Programs at the European Association for the Study of the Liver (EASL) Congress 2025

      Phase 2 SOLSTICE subgroup analysis data in chronic hepatitis delta selected for poster presentation, and to be highlighted during EASL poster tour 24 Week post-treatment follow-up data in chronic hepatitis B from MARCH Phase 2 study to be shared in oral presentation Vir Biotechnology, Inc. (NASDAQ:VIR) today announced the Company will present data from a 24-week subgroup analysis of its ongoing Phase 2 SOLSTICE trial in chronic hepatitis delta at the upcoming European Association for the Study of the Liver (EASL) Congress 2025 in Amsterdam (The Netherlands), May 7-10. The Company will also present 24 Week post-treatment follow-up data from the MARCH Phase 2 clinical study evaluating c

      4/24/25 9:30:00 AM ET
      $VIR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $VIR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Vir Biotechnology downgraded by JP Morgan with a new price target

      JP Morgan downgraded Vir Biotechnology from Overweight to Neutral and set a new price target of $9.00 from $23.00 previously

      1/29/24 7:27:38 AM ET
      $VIR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Vir Biotechnology downgraded by BofA Securities with a new price target

      BofA Securities downgraded Vir Biotechnology from Buy to Neutral and set a new price target of $14.00 from $23.00 previously

      9/8/23 7:28:27 AM ET
      $VIR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Vir Biotechnology upgraded by JP Morgan with a new price target

      JP Morgan upgraded Vir Biotechnology from Neutral to Overweight and set a new price target of $34.00 from $35.00 previously

      3/6/23 7:36:08 AM ET
      $VIR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $VIR
    SEC Filings

    See more
    • Vir Biotechnology Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Vir Biotechnology, Inc. (0001706431) (Filer)

      5/7/25 4:13:38 PM ET
      $VIR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form DEFA14A filed by Vir Biotechnology Inc.

      DEFA14A - Vir Biotechnology, Inc. (0001706431) (Filer)

      4/17/25 8:40:10 AM ET
      $VIR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form DEF 14A filed by Vir Biotechnology Inc.

      DEF 14A - Vir Biotechnology, Inc. (0001706431) (Filer)

      4/17/25 8:33:55 AM ET
      $VIR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $VIR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Executive Officer De Backer Marianne sold $474,239 worth of shares (79,712 units at $5.95), decreasing direct ownership by 9% to 769,505 units (SEC Form 4)

      4 - Vir Biotechnology, Inc. (0001706431) (Issuer)

      4/4/25 4:23:39 PM ET
      $VIR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • EVP and General Counsel De Verneuil Vanina sold $67,402 worth of Common Stock (7,373 units at $9.14), decreasing direct ownership by 8% to 79,460 units (SEC Form 4)

      4 - Vir Biotechnology, Inc. (0001706431) (Issuer)

      2/27/25 12:39:28 PM ET
      $VIR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Scangos George A sold $95,063 worth of shares (10,056 units at $9.45), decreasing direct ownership by 1% to 698,239 units (SEC Form 4)

      4 - Vir Biotechnology, Inc. (0001706431) (Issuer)

      2/25/25 3:44:56 PM ET
      $VIR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $VIR
    Leadership Updates

    Live Leadership Updates

    See more
    • Vir Biotechnology Appoints Jason O'Byrne as Chief Financial Officer

      – Seasoned biotech executive brings decades of effective financial leadership to Vir – Vir Biotechnology Inc. (NASDAQ:VIR) today announced that Jason O'Byrne, MBA, is appointed as Executive Vice President and Chief Financial Officer (CFO), effective October 2, 2024. Mr. O'Byrne will join the Vir Executive Management Team and report directly to the company's Chief Executive Officer, Marianne De Backer, M.Sc., Ph.D., MBA. Mr. O'Byrne is an accomplished executive with more than 20 years of experience in finance and operations. He is a recognized champion of financial discipline and brings demonstrated financial leadership in capital allocation and formation, corporate strategy, and operation

      9/10/24 8:05:00 AM ET
      $VIR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Lineage Announces Appointment of Charlotte Hubbert, Ph.D., as Vice President of Corporate Development

      Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced the appointment of veteran industry executive Charlotte Hubbert, Ph.D., as Vice President of Corporate Development. Dr. Hubbert has an extensive background in cell therapy research and venture investment across a broad range of therapeutic modalities and development stages, and has a proven ability to combine deep scientific expertise and business development acumen to identify innovative opportunities to drive both returns and impact. Dr. Hubbert previously served as Partner and Head of Gates Foundation Venture

      4/1/24 8:00:00 AM ET
      $LCTX
      $SYBX
      $VIR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • Vir Biotechnology Appoints Jennifer Towne, Ph.D., as Executive Vice President and Chief Scientific Officer

      Vir Biotechnology, Inc. (NASDAQ:VIR) today announced the appointment of Jennifer Towne, Ph.D., as Executive Vice President and Chief Scientific Officer, effective November 6, 2023. Dr. Towne will be responsible for leading the Company's research function from basic research through scale-up manufacturing and the introduction of drug candidates to clinical trials. She will report to Vir's Chief Executive Officer Marianne De Backer, M.Sc., Ph.D., MBA, and will join the Company's Executive Management Team. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231026830042/en/Jennifer Towne, Ph.D., appointed as Executive Vice President and

      10/30/23 8:00:00 AM ET
      $VIR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $VIR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Vir Biotechnology Inc.

      SC 13G/A - Vir Biotechnology, Inc. (0001706431) (Subject)

      10/18/24 12:29:43 PM ET
      $VIR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Vir Biotechnology Inc. (Amendment)

      SC 13G/A - Vir Biotechnology, Inc. (0001706431) (Subject)

      2/13/24 5:17:30 PM ET
      $VIR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Vir Biotechnology Inc. (Amendment)

      SC 13G/A - Vir Biotechnology, Inc. (0001706431) (Subject)

      2/13/24 5:00:42 PM ET
      $VIR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $VIR
    Financials

    Live finance-specific insights

    See more
    • Vir Biotechnology Provides Corporate Update and Reports First Quarter 2025 Financial Results

      - Initiated Phase 3 registrational ECLIPSE program in chronic hepatitis delta with first patient enrolled in Q1 2025; Program received U.S. FDA Breakthrough and Fast Track designations and EMA PRIME and Orphan Drug designations - Dose escalation continues for PRO-XTEN™ dual-masked T-cell engagers VIR-5818 (HER2) and VIR-5500 (PSMA) - On track to initiate a Phase 1 study of VIR-5525, the PRO-XTEN™ dual-masked EGFR-targeting T-cell engager, in the second quarter of 2025 - 24-week post-treatment data from Phase 2 MARCH study in chronic hepatitis B to be presented at EASL on May 9; Further development requires partner - Strong financial position with approximately $1.0 billion in cash and i

      5/7/25 4:05:00 PM ET
      $VIR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Vir Biotechnology to Provide Corporate Update and Report First Quarter 2025 Financial Results on May 7, 2025

      Vir Biotechnology, Inc. (NASDAQ:VIR) today announced that the Company will provide a corporate update and report financial results for the first quarter ended March 31, 2025, on May 7, 2025. The Company will host a conference call at 1:30 p.m. PT / 4:30 p.m. ET on May 7, 2025. The corporate update and financial results will be provided via a press release shortly after market close and will be accessible on the News page in the Investors section of the Vir Biotechnology website. Participants may access the conference call via webcast on the Events & Presentations page of the Vir Biotechnology website or via phone by dialing the U.S. toll free number +1 (888) 800-8770 or international numbe

      4/30/25 4:05:00 PM ET
      $VIR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Brii Biosciences Provides Corporate Update and Reports Full-Year 2024 Financial Results

      Strategic Acquisition of Intellectual Property of BRII-179, a Wholly Owned Phase 2b Asset Capable of Combining with Multiple HBV Treatment Modalities for Cure Data from Multiple Ongoing Late-Stage Studies Reinforce Brii Bio's HBV Functional Cure Strategy of Optimized Combination Regimens to Target Patient Populations 4 Abstracts Including 2 Oral Presentations with Data from the Ongoing Phase 2 ENSURE Study at the Upcoming APASL (March 26-30) Strong Cash Reserves of US$335.7 Million to Propel Operations into 2028 Actively Seeking Partnership Opportunities for Non-HBV Programs Conference Call (English Session) Scheduled for March 31 at 8:30 PM HKT / 8:30 AM ET DURHAM, N.C. and BEIJING, China,

      3/21/25 7:10:00 AM ET
      $VIR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care